Related Experiment Video

Updated: Aug 24, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Combination therapy for the treatment of dyslipidemia

Dan Streja1

  • 1Sections of Endocrinology and Cardiology, VA Medical Center of West Los Angeles, Los Angeles, CA 90073, USA. dstreja@ucla.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|April 16, 2004
PubMed

Insights

Statins are effective but don't fully protect two-thirds of patients from cardiovascular events. New therapies targeting high-density lipoprotein (HDL) and very low-density lipoprotein (VLDL) are being explored to improve cardiovascular prevention.

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Disorders

Background:

  • Statins are recommended for cardiovascular prevention but fail to protect two-thirds of patients.
  • The rising prevalence of metabolic syndrome and type 2 diabetes increases dyslipidemia.
  • There is a need for additional therapies to improve cardiovascular risk reduction.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for dyslipidemia beyond statin monotherapy.
  • To evaluate the potential of combination therapies and novel drug classes for cardiovascular risk reduction.

Main Methods:

  • Review of clinical trial data on statin combination therapies (fibrates, niacin).
  • Discussion of emerging drug classes: CETP inhibitors and HDL therapy agents.
  • Analysis of lipoprotein metabolism and function in the context of dyslipidemia.

Main Results:

  • Statin-fibrate combination therapy requires further safety trials.
  • Statin-niacin combination therapy is safe and effective for lipoprotein patterns, needing more mechanistic research.
  • CETP inhibitors and HDL therapy drugs show promise but are in early development.

Conclusions:

  • Combination therapies and novel agents are crucial for optimizing cardiovascular prevention in dyslipidemic patients.
  • Further research is needed to establish the safety and efficacy of new treatment strategies.
  • Targeting HDL and VLDL metabolism offers promising avenues for future cardiovascular therapies.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...